{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "\u0426\u0435\u043b\u044c \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f - \u0432\u044b\u044f\u0432\u043b\u0435\u043d\u0438\u0435 \u0444\u0430\u043a\u0442\u043e\u0440\u043e\u0432, \u0432\u043b\u0438\u044f\u044e\u0449\u0438\u0445 \u043d\u0430 \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u0432\u0435\u043d\u043b\u0430\u0444\u0430\u043a\u0441\u0438\u043d\u0430 \u043f\u0440\u0438 \u0443\u043c\u0435\u0440\u0435\u043d\u043d\u044b\u0445 \u0438 \u0442\u044f\u0436\u0435\u043b\u044b\u0445 \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u044f\u0445. \u041c\u0430\u0442\u0435\u0440\u0438\u0430\u043b \u0438 \u043c\u0435\u0442\u043e\u0434\u044b. \u0411\u044b\u043b\u043e \u043f\u0440\u043e\u0432\u0435\u0434\u0435\u043d\u043e \u043d\u0430\u0431\u043b\u044e\u0434\u0430\u0442\u0435\u043b\u044c\u043d\u043e\u0435 \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0435 \u0432 \u0443\u0441\u043b\u043e\u0432\u0438\u044f\u0445 \u0440\u0435\u0430\u043b\u044c\u043d\u043e\u0439 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u043f\u0440\u0430\u043a\u0442\u0438\u043a\u0438. \u041e\u0431\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043b\u0438 62 \u043f\u0430\u0446\u0438\u0435\u043d\u0442\u0430 \u0441 \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u0435\u0439, 21 \u043c\u0443\u0436\u0447\u0438\u043d\u0443 \u0438 41 \u0436\u0435\u043d\u0449\u0438\u043d\u0443, \u0432 \u0432\u043e\u0437\u0440\u0430\u0441\u0442\u0435 \u043e\u0442 19 \u043b\u0435\u0442 \u0434\u043e 61 \u0433\u043e\u0434\u0430, \u043b\u0435\u0447\u0438\u0432\u0448\u0438\u0445\u0441\u044f \u0432\u0435\u043d\u043b\u0430\u0444\u0430\u043a\u0441\u0438\u043d\u043e\u043c. \u0422\u0435\u0440\u0430\u043f\u0438\u044f \u043f\u0440\u043e\u0434\u043e\u043b\u0436\u0430\u043b\u0430\u0441\u044c 84 \u0434\u043d\u044f (\u0441\u043d\u0430\u0447\u0430\u043b\u0430 \u0432 \u0441\u0442\u0430\u0446\u0438\u043e\u043d\u0430\u0440\u0435, \u0437\u0430\u0442\u0435\u043c \u0430\u043c\u0431\u0443\u043b\u0430\u0442\u043e\u0440\u043d\u043e). \u041d\u0430\u0447\u0430\u043b\u044c\u043d\u0430\u044f \u0434\u043e\u0437\u0430 \u0432\u0435\u043d\u043b\u0430\u0444\u0430\u043a\u0441\u0438\u043d\u0430 \u0441\u043e\u0441\u0442\u0430\u0432\u043b\u044f\u043b\u0430 75 \u043c\u0433/\u0441\u0443\u0442, \u0441\u0440\u0435\u0434\u043d\u044f\u044f \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0430\u044f - 225 \u043c\u0433/\u0441\u0443\u0442. \u0421\u043e\u0441\u0442\u043e\u044f\u043d\u0438\u0435 \u0431\u043e\u043b\u044c\u043d\u044b\u0445 \u043e\u0446\u0435\u043d\u0438\u0432\u0430\u043b\u0438 \u043a\u043b\u0438\u043d\u0438\u043a\u043e-\u043f\u0441\u0438\u0445\u043e\u043f\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u043c \u043c\u0435\u0442\u043e\u0434\u043e\u043c \u0438 \u043f\u043e \u0440\u044f\u0434\u0443 \u0448\u043a\u0430\u043b (MADRS, \u0448\u043a\u0430\u043b\u0430 \u0411\u0435\u043a\u0430, CGI, UKU). \u0420\u0435\u0437\u0443\u043b\u044c\u0442\u0430\u0442\u044b \u0438 \u0437\u0430\u043a\u043b\u044e\u0447\u0435\u043d\u0438\u0435. \u0423\u0441\u0442\u0430\u043d\u043e\u0432\u0438\u043b\u0438 \u0432\u044b\u0441\u043e\u043a\u0443\u044e \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u0438\u0437\u0443\u0447\u0430\u0432\u0448\u0435\u0433\u043e\u0441\u044f \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430 \u043f\u0440\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0442\u044f\u0436\u0435\u043b\u044b\u0445 \u0438 \u0443\u043c\u0435\u0440\u0435\u043d\u043d\u044b\u0445 \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u0439. \u0412\u0435\u043d\u043b\u0430\u0444\u0430\u043a\u0441\u0438\u043d \u043e\u0431\u043b\u0430\u0434\u0430\u043b \u043d\u0430\u0438\u0431\u043e\u043b\u044c\u0448\u0435\u0439 \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c\u044e \u043f\u0440\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0442\u0440\u0435\u0432\u043e\u0436\u043d\u043e\u0439 \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u0438, \u043d\u0430\u0438\u043c\u0435\u043d\u044c\u0448\u0435\u0439 - \u043f\u0440\u0438 \u0438\u043f\u043e\u0445\u043e\u043d\u0434\u0440\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u0438. \u041f\u0440\u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u0442\u044f\u0436\u0435\u043b\u044b\u0445 \u0438 \u0443\u043c\u0435\u0440\u0435\u043d\u043d\u044b\u0445 \u0434\u0435\u043f\u0440\u0435\u0441\u0441\u0438\u0439 \u0431\u044b\u0441\u0442\u0440\u043e\u0435 \u043d\u0430\u0440\u0430\u0449\u0438\u0432\u0430\u043d\u0438\u0435 \u0434\u043e\u0437\u044b \u0432\u0435\u043d\u043b\u0430\u0444\u0430\u043a\u0441\u0438\u043d\u0430 \u043f\u043e\u0437\u0432\u043e\u043b\u044f\u0435\u0442 \u043f\u043e\u043b\u0443\u0447\u0438\u0442\u044c \u043e\u0442\u0432\u0435\u0442 \u043d\u0430 \u0442\u0435\u0440\u0430\u043f\u0438\u044e \u0432 \u0431\u043e\u043b\u0435\u0435 \u043a\u043e\u0440\u043e\u0442\u043a\u0438\u0439 \u0441\u0440\u043e\u043a, \u0431\u0435\u0437 \u0443\u0445\u0443\u0434\u0448\u0435\u043d\u0438\u044f \u043f\u0435\u0440\u0435\u043d\u043e\u0441\u0438\u043c\u043e\u0441\u0442\u0438 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0430."
      ]
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "25909786",
  "DateCompleted": {
    "Year": "2015",
    "Month": "07",
    "Day": "07"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "rus"
    ],
    "ELocationID": [
      "10.17116/jnevro20151151130-34"
    ],
    "Journal": {
      "ISSN": "1997-7298",
      "JournalIssue": {
        "Volume": "115",
        "Issue": "1",
        "PubDate": {
          "Year": "2015"
        }
      },
      "Title": "Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova",
      "ISOAbbreviation": "Zh Nevrol Psikhiatr Im S S Korsakova"
    },
    "ArticleTitle": "[Venlafaxine in the treatment of moderate and severe depressions: the ways to increase treatment efficacy].",
    "Pagination": {
      "StartPage": "30",
      "EndPage": "34",
      "MedlinePgn": "30-34"
    },
    "Abstract": {
      "AbstractText": [
        "To find factors influencing the efficacy of venlafaxine in moderate and severe depressions.",
        "An observational study was carried out in real clinical practice. We examined 62 patients with depression, 21 men and 41 women, aged from 19 to 61 years, treated with venlafaxine. The duration of treatment was 84 days (first at the hospital and then at home). The initial dose was 75 mg daily, mean therapeutic dose 225 mg daily. Patient's status was assessed using clinical/psychological methods and psychometric scales (MADRS, Beck scale, CGI, UKU).",
        "The high efficacy of the drug in the treatment of severe and moderate depressions was demonstrated. Venlafaxine was mostly effective in the treatment of anxious depression and less effective for hypochondriac depression. The rapid increase in dose of venlafaxine makes it possible to reach treatment effect in shorter time without worsening drug tolerability."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Sechenov First Moscow State Medical University, Moscow."
          }
        ],
        "LastName": "Ivanets",
        "ForeName": "N N",
        "Initials": "NN"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Sechenov First Moscow State Medical University, Moscow."
          }
        ],
        "LastName": "Kinkulkina",
        "ForeName": "M A",
        "Initials": "MA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Sechenov First Moscow State Medical University, Moscow."
          }
        ],
        "LastName": "Tikhonova",
        "ForeName": "Yu G",
        "Initials": "YG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Sechenov First Moscow State Medical University, Moscow."
          }
        ],
        "LastName": "Iziumina",
        "ForeName": "T A",
        "Initials": "TA"
      }
    ],
    "PublicationTypeList": [
      "English Abstract",
      "Journal Article",
      "Observational Study"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Russia (Federation)",
    "MedlineTA": "Zh Nevrol Psikhiatr Im S S Korsakova",
    "NlmUniqueID": "9712194",
    "ISSNLinking": "1997-7298"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antidepressive Agents, Second-Generation"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cyclohexanols"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Serotonin Uptake Inhibitors"
    },
    {
      "RegistryNumber": "7D7RX5A8MO",
      "NameOfSubstance": "Venlafaxine Hydrochloride"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "therapeutic use"
      ],
      "DescriptorName": "Antidepressive Agents, Second-Generation"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "therapeutic use"
      ],
      "DescriptorName": "Cyclohexanols"
    },
    {
      "QualifierName": [
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Depressive Disorder, Major"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Psychiatric Status Rating Scales"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "therapeutic use"
      ],
      "DescriptorName": "Selective Serotonin Reuptake Inhibitors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Venlafaxine Hydrochloride"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Young Adult"
    }
  ]
}